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The neurotrophin receptor TrkA plays critical roles in the nervous system by recruiting signaling molecules
that activate pathways required for the growth and survival of neurons. Here, we report APPL1 as a TrkA-
associated protein. APPL1 and TrkA coimmunoprecipitated in sympathetic neurons. We have identified two
routes through which this association can occur. APPL1 was isolated as a binding partner for the TrkA-
interacting protein GIPC1 from rat brain lysate by mass spectrometry. The PDZ domain of GIPC1 directly
engaged the C-terminal sequence of APPL1. This interaction provides a means through which APPL1 may be
recruited to TrkA. In addition, the APPL1 PTB domain bound to TrkA, indicating that APPL1 may associate
with TrkA independently of GIPC1. Isolation of endosomal fractions by high-resolution centrifugation deter-
mined that APPL1, GIPC1, and phosphorylated TrkA are enriched in the same fractions. Reduction of APPL1
or GIPC1 protein levels suppressed nerve growth factor (NGF)-dependent MEK, extracellular signal-regulated
kinase, and Akt activation and neurite outgrowth in PC12 cells. Together, these results indicate that GIPC1
and APPL1 play a role in TrkA function and suggest that a population of endosomes bearing a complex of
APPL1, GIPC1, and activated TrkA may transmit NGF signals.
The TrkA receptor tyrosine kinase is essential for the devel-
opment and function of the vertebrate nervous system. As a
receptor for the prototypic neurotrophin nerve growth factor
(NGF), TrkA propagates NGF-induced signaling cascades re-
quired for the survival, differentiation, growth, and function of
neurons. Within the peripheral nervous system, NGF and
other members of the neurotrophin family are target derived
and secreted in limiting amounts to ensure appropriate inner-
vation by supporting the survival of only those neurons that
have made the correct connections (21, 22). In particular, once
axons have reached their targets, NGF binds to TrkA on ax-
onal terminals. The subsequent activation of TrkA stimulates
the activities of the mitogen-activated protein kinase (MAPK),
phosphatidylinositol (PI) 3-kinase/Akt, and phospholipase C
(PLC)- pathways (19, 28). A number of these NGF-mediated
signals are transmitted in a retrograde fashion from the termi-
nal along the axon to the cell body and, ultimately, to the
nucleus to elicit transcriptional responses. Those neurons that
receive sufficient retrograde survival and growth signals survive
and innervate their targets, while those that do not are elimi-
nated by apoptosis.
Accumulating evidence indicates that one means by which
the retrograde signal is transduced is in an endosome (2, 9, 15)
that is generated by internalization of the TrkA receptor
through both clathrin-dependent (14) and clathrin-indepen-
dent (30, 35) mechanisms. Within the endosome, NGF, acti-
vated TrkA, and components of TrkA signaling pathways are
found together and create a discrete signaling unit that is
transported along the axon to the cell body (4, 6, 7, 10, 11, 14,
18, 33, 37, 40). Thus, TrkA functions not only as a receptor at
the plasma membrane but also as a signaling entity within the
cell. In this manner, the signaling function of TrkA is also tied
to its trafficking.
While a number of interacting partners for TrkA have been
identified, relatively few proteins have been shown to link
TrkA signaling to its trafficking. One TrkA-associated protein
that may fulfill this function is the PDZ domain-containing
protein GIPC1. GIPC1 is constitutively associated with TrkA
and TrkB through direct binding to the juxtamembrane region
of the receptor. Overexpression of GIPC1 in PC12 cells de-
creases NGF-induced extracellular signal-regulated kinase 1
(ERK1) and ERK2 activation, implicating GIPC1 in TrkA
signaling (24). Several lines of evidence suggest that GIPC1
may be involved in endocytosis and early trafficking events.
GIPC1 localizes to clathrin-coated pits and peripheral endo-
somes in the rat kidney and in ARPE-19 retinal pigmented
epithelial cells (1, 23). A potential function for GIPC1 in ve-
sicular transport is suggested by its association with motor
proteins KIF-1B and myosin VI (5). In NGF-treated PC12
cells, phosphorylated TrkA (pTrkA) and GIPC1 colocalize in
endocytic structures (24). GIPC1 has been postulated to act as
a scaffolding protein and, as such, could act to recruit other
proteins to TrkA, nucleating multiprotein complexes impor-
tant for TrkA signaling and trafficking.
One family of molecules that has been shown to link signal-
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ing and trafficking downstream of receptor tyrosine kinases are
the APPL proteins. APPL1 and APPL2 act to couple receptor
trafficking to epidermal growth factor (EGF) signaling via an
endocytic compartment in HeLa cells (26). APPL associates
with the small-molecular-weight GTPase Rab5, a key regulator
of transport from the plasma membrane to the early endosome
(32, 41). Upon EGF treatment and subsequent hydrolysis of
GTP-Rab5, APPL1 and APPL2 are released from the plasma
membrane and translocate to the nucleus, where they associate
with components of the nucleosome remodeling and histone
deacetylation machinery. The endosomal signaling pathway
mediated by APPL1 and APPL2 links signaling events at the
plasma membrane with chromatin remodeling in the nucleus
and is essential for cell proliferation.
In the present study, we have identified APPL1 as a new
TrkA-interacting protein. APPL1 associates with TrkA
through two different means: indirectly via GIPC1 through a
PDZ domain-mediated interaction and directly through the
APPL1 phosphotyrosine binding (PTB) domain. Cell fraction-
ation studies demonstrate that APPL1, GIPC1, and pTrkA are
present in the same endosomal fractions. Last, we demonstrate
roles for APPL1 and GIPC1 in TrkA function by determining
that both proteins are required for NGF-induced MEK,
ERK1/2, and Akt activation and neurite outgrowth. This study
extends the function of APPL1 to neurotrophin receptor sig-
naling and is consistent with a potential role for APPL1 in the
signaling endosome downstream of NGF.
MATERIALS AND METHODS
Constructs, mutagenesis, fusion proteins, and antibodies. The Flag-GIPC1
pcDNA3 (Invitrogen) template was kindly provided by Moses Chao. For gluta-
thione-S-transferase (GST) fusion constructs, cDNA sequences of rat GIPC1
(full length, residues 1 to 333; N terminus, residues 1 to 108; N terminus plus
PDZ, residues 1 to 216; PDZ, residues 109 to 216; C terminus, residues 216 to
333) were cloned into the pGEX2 vector (GE Healthcare). Constructs encoding
APPL1 fusion proteins were created by amplifying regions of the human APPL1
cDNA corresponding to the full length (residues 1 to 709), the Bin-amphiphysin-
Rvs (BAR) domain (residues 1 to 269), the pleckstrin homology (PH) domain
(residues 263 to 480), the PTB domain (residues 472 to 655), and the PTB
domain plus the C terminus (residues 472 to 709) and subcloning in frame into
pFLAG CMV2 (where CMV is cytomegalovirus), pEYFP (where EYFP is en-
hanced yellow fluorescent protein) (Clontech), pGEX4T3 (GE Healthcare), or
pPRO EX HTc (Invitrogen). Constructs encoding TrkA fusion proteins were
generated by amplifying segments of human TrkA cDNA corresponding to the
juxtamembrane region (residues 434 to 510), the kinase domain (residues 502 to
660), and the C-terminal region (residues 660 to 790) and subcloning in frame
into pPRO EX HTc. Mutations in the GIPC1 and APPL1 cDNAs were gener-
ated using a QuikChange site-directed mutagenesis kit (Stratagene). All fusion
constructs and mutations were confirmed by sequencing. GST and His fusion
constructs were used to transform an Escherichia coli BL21 strain, and the
recombinant fusion proteins were purified using standard procedures.
Rabbit polyclonal antibodies were raised separately against GST fusions of
full-length GIPC1 and APPL1 PTB plus the C terminus. Rabbits were immu-
nized and boosted at 6-week intervals by use of standard methods. Antibodies
against APPL1 were affinity purified by applying raw sera to a GST-Sepharose
column to deplete anti-GST antibodies, followed by enrichment through a GST-
APPL1 PTB plus C terminus Sepharose column. Rabbit anti-TrkA RTA was a
gift from L. Reichardt (University of California, San Francisco, CA). The rabbit
anti-pan-Trk antibody has been described previously (12). Other antibodies used
were mouse anti-Flag M2 (Sigma); mouse anti-tetra-His (QIAGEN); mouse
antiphosphotyrosine (4G10; Upstate Biotechnology); rabbit anti-phospho-
(Tyr490) TrkA, rabbit anti-p(Ser-217/Ser-221) MEK, rabbit anti-MEK, rabbit
anti-phospho(Tyr317) Shc, rabbit anti-Akt, and rabbit anti-phospho(Ser-473)
Akt (Cell Signaling); rabbit anti-phospho(Thr-183/Tyr-185) ERK (Promega);
mouse anti-green fluorescent protein (anti-GFP) (Molecular Probes); rabbit
anti-ShcA (Upstate Biotechnology); mouse anti-Trk (Zymed); and rabbit anti-
ERK1 (Santa Cruz).
Mass spectrometry and peptide analysis. Adult rat brains were homogenized
in 10 mM HEPES, pH 7.4, supplemented with Mini Complete protease inhibitor
cocktail (Roche) and 1.5 mM sodium vanadate. Triton X-100 was added to 1%,
and the homogenate was incubated at 4°C for 20 min. The soluble fraction was
isolated through centrifugation at 10,000  g for 30 min at 4°C. Lysates were
incubated with 5 g GST-GIPC1 fusion protein for 2 h at 4°C. Beads were
subsequently washed three times in lysis buffer containing 1% Triton X-100.
GST-GIPC1-associated proteins were separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie bril-
liant blue. Bands were excised, reduced, alkylated, and in-gel trypsin digested as
described previously (36a). The resulting peptide extracts were analyzed by
employing a nanoscale liquid chromatography quadrupole time of flight mass
spectrometer. The resulting MS were analyzed by Mascot software (cluster
version 1.9.03).
Cell culture, primary sympathetic neuron cultures, transfection, and growth
factors. COS7 cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum, 120 g/ml penicillin, 200
g/ml streptomycin sulfate, and 600 g/ml glutamine. PC12 (clone 6-24) cells
which stably overexpress TrkA (12) were maintained in DMEM containing 10%
horse serum, 5% bovine calf serum, 120 g/ml penicillin, 200 g/ml streptomycin
sulfate, 600 g/ml glutamine, and 200 g/ml Geneticin (Invitrogen). Mass cul-
tures of sympathetic neurons derived from the superior cervical ganglia (SCG) of
postnatal day 1 Sprague-Dawley rats were prepared and cultured as described
previously (34). NGF was withdrawn from sympathetic neuron cultures by per-
forming three 1.5-h washes in Ultraculture medium (Cambrex) without NGF.
For neurotrophin inductions, NGF at a final concentration of 50 ng/ml was
added to the media for 10 min prior to cell lysis. For experiments performed in
the presence of Trk inhibitor, 200 nM K252a (Calbiochem) was added to sym-
pathetic neuron cultures prior to NGF treatment. Transient transfections were
performed using Lipofectamine 2000 and Opti-MEM as outlined by the manu-
facturer (Invitrogen). For transient transfection of SCG cultures, primary cul-
tures were transfected at the time of plating in Ultraculture medium containing
120 g/ml penicillin, 200 g/ml streptomycin sulfate, 600 g/ml glutamine,
50 ng/ml nerve growth factor, 3% rat serum (Wisent, Inc.), 0.7% cytosine -
arabinofuranoside (Sigma), and 50 mM potassium chloride. NGF was obtained
from Cedarlane Labs, Ltd.
Recombinant adenovirus and viral infection. Replication-defective recombi-
nant adenovirus encoding wild-type human TrkAI containing a Flag tag epitope
in the extracellular domain has been described previously (20). Viral infections
of sympathetic neurons were performed as described previously (25, 36). Cells
were infected with 100 multiplicities of infection of virus overnight and assayed
48 h after infection.
Immunoprecipitation and Western blot analysis. Cells were rinsed twice in
ice-cold phosphate-buffered saline (PBS) and lysed in PLC lysis buffer supple-
mented with 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM sodium vanadate, and
1 mM phenylmethylsulfonyl fluoride (PMSF) (13). Immunoprecipitations were
performed for 2 h at 4°C with antibodies at a concentration of 1 g/ml and either
protein A or goat anti-mouse Sepharose. GST mixing experiments were carried
out by incubating lysate with 5 g of fusion protein immobilized on glutathione-
Sepharose for 2 h at 4°C. To measure direct binding of GIPC1 to APPL1, 1 g
of bacterially produced, purified His-tagged fragments of APPL1 was incubated
with 5 g of the purified recombinant GST-GIPC1 fusion proteins bound to
glutathione-Sepharose. Experiments to assay direct binding of APPL1 to TrkA
were performed by incubating 1 g of bacterially produced, purified His-tagged
fragments of TrkA with 5 g of the purified recombinant GST-APPL1 fusion
proteins bound to glutathione-Sepharose. For the peptide mixing experiments,
1.25 nmol of biotinylated TrkA or pTrkA peptide or, as a negative control, 1.25
nmol of biotin was incubated with 15 l of high-performance streptavidin Sepha-
rose (GE Healthcare) for 1 h at 4°C. Beads were washed twice in PLC buffer to
remove unbound peptide and then incubated with 2 mg of PC12 (6-24) lysate for
2 h at 4°C. The TrkA Shc-binding site peptide of sequence biotin-Aca-AAVAL
LPAVLLALLAPHIIENPQYFSD and the related phosphopeptide biotin-Aca-
AAVALLPAVLLALLAPHIIENPQpYFSD were a kind gift from Jerry Gish. In
both immunoprecipitation and mixing experiments, beads were washed three
times in HNTG buffer containing 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM
sodium vanadate, and 1 mM PMSF (13). Proteins were separated by SDS-
PAGE, transferred to nitrocellulose membrane, and immunoblotted with the
appropriate antibody. Blots were developed by enhanced chemiluminescence
(GE Healthcare). For Western blot analysis of endosomal fractions, lumines-
cence was measured using a cooled charge-coupled-device camera with a Fuji
LAS-3000 system and data were quantified with Fuji Image Gauge software.
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Densitometric analyses of other immunoblots were performed on scanned films
with Total Lab 1.0 software (GE Healthcare). Intensity values were normalized
to measurements of the ERK1 and MEK loading controls.
Preparation of endosomal fractions. PC12 cells (109) grown on collagen-
coated plates in RPMI 1640, 5% fetal calf serum, and 10% horse serum were
harvested in ice-cold PBS. Cells were rinsed in PBS containing 1 mM EGTA and
1 mM EDTA, followed by one wash in PBS with 0.1% glucose and 0.1% bovine
serum albumin (PGB). To ensure precise control of internalization time, cells
were treated with 50 ng/ml NGF at 4°C in PGB for 1 h to allow binding to the
receptor, washed in PGB to remove unbound ligand so as to avoid fluid-phase
endocytosis, and warmed in PGB to 37°C for 10 min, followed by a temperature
quench in ice water. Following washes in PBS containing 1 mM EGTA and 1 mM
EDTA and then buffer B (cytoplasmic ionic composition of 38 mM each of the
K salts of aspartic acid, glutamic acid, and gluconic acid, 20 mM MOPS
[morpholinepropanesulfonic acid], pH 7.1, at 37°C, 10 mM potassium bicarbon-
ate, 0.5 mM magnesium carbonate, 1 mM EDTA, 1 mM EGTA), cells were
resuspended in buffer B supplemented with 5 mM reduced glutathione, protease
inhibitors (0.1 g/ml aprotinin, chymostatin, leupeptin, and pepstatin A; 1 g/ml
1,10-phenanthroline; 10 g/ml bisbenzamide; and 1 mM PMSF), and phos-
phatase inhibitors (100 nM calyculin A and 1 mM sodium vanadate). Mechanical
permeabilization of cells was performed by a single passage through a Balch
homogenizer as described previously (10, 11).
Semi-intact cells and large membranes were removed from the permeabilized
cell suspension by centrifugation at 1,000  g. The resulting supernatant (S1) was
layered over a 0 to 30% iodixanol velocity gradient and centrifuged at 133,000 
g for 1.5 h. Five fractions were collected from velocity gradients and further
resolved by equilibrium gradient centrifugation: fractions were mixed with 60%
iodixanol to a concentration of 32.5% or greater, overlaid with a continuous 0 to
30% iodixanol-buffer B plus glutathione gradient, and centrifuged to equilibrium
(16 to 18 h). Twenty-four fractions were collected from each equilibrium gradi-
ent. To determine density, refractive indices were measured using an Abbe
refractometer (Bausch and Lomb) and converted to density using the formula
  RI  3.4319  3.5851, where RI is refractive index. This formula was deter-
mined empirically by weighing known concentrations of iodixanol in buffer B.
siRNA preparation and transfection. Duplex small interfering RNAs (siRNAs)
targeted against rat APPL1 (5	-CUCACCUGACUUCGAAACUTT and
5	-AGUUUCGAAGUCAGGUGAGTT) or against rat GIPC1 (5	-AGAGGU
GGAAGUAUUCAAGTT and 5	-CUUGAAUACUUCCACCUCUTT) or of a
nonspecific sequence (5	-UCUUGUCGAUCGGUGUUCUTT and 5	-AGAAC
ACCGAUCGACAAGATT) were purchased from Dharmacon. For biochemical
studies, PC12 (6-24) cells plated in 12-well tissue culture plates at a density of
16,000 cells per well were transfected 24 h later with 100 nM of siRNA oligo-
nucleotides by use of Lipofectamine 2000. To evaluate NGF-induced ERK and
Akt activation, cells were rinsed twice in DMEM at 3-h intervals to remove
serum 42 h posttransfection. Forty-eight hours following transfection, 50 ng/ml
NGF was added to the medium for 10 min and cell lysates were prepared for
analysis. For neurite outgrowth assays, PC12 (6-24) cells plated on 30 g/ml
poly-L-lysine in 12-well tissue culture plates at a density of 16,000 cells per well
were cotransfected with 1 g pEGFP (where EGFP is enhanced green fluores-
cent protein) (Clontech) and 100 nM of siRNA oligonucleotides. Cells were
treated with 50 ng/ml NGF in DMEM containing 0.5% horse serum 24 h
posttransfection to allow neurite outgrowth. Following 48 h of NGF treatment,
images were captured using a Retiga Exi digital camera (Q-imaging) on a Zeiss
Axiovert 200 M inverted microscope equipped with fluorescence optics. For each
condition, 24 images of random fields were taken at a 20 magnification from
two wells. Neurite lengths of GFP-positive cells were measured using Northern
Eclipse software (Empix Imaging). The experiment was performed three times.
From the three experiments, the total number of cells analyzed was 279 for
APPL1 siRNA/pEGFP-cotransfected cells, 359 for GIPC1/pEGFP-cotransfected
cells, and 563 for siRNA control/pEGFP-cotransfected cells. Statistical analyses
were carried out using SAS software, version 8.02 (SAS Institute, Inc.). Tukey
and Bonferroni tests were performed using the generalized linear model proce-
dure. MTT (3-[4,5-dimethylthiazol-2-l]-2,5-diphenyltetrazolium) assays were
performed as previously described (36).
Immunofluorescence microscopy. Cells were rinsed briefly in PBS, fixed with
4% paraformaldehyde in PBS for 20 min, permeabilized with 0.1% Triton X-100
in PBS for 5 min, and placed in blocking solution (5% bovine serum albumin, 5%
normal goat serum, and 0.01% Tween 20 in PBS) for 1 h at room temperature.
Single- or double-label immunofluorescence staining procedures were employed
to detect endogenous APPL1, endogenous TrkA, and exogenous Flag-GIPC1.
Samples were incubated overnight at 4°C with primary antibodies at a concen-
tration of 1 g/ml in blocking solution. Alexa 488-conjugated anti-mouse, Alexa
488-conjugated anti-rabbit, Alexa 555-conjugated anti-mouse, and Alexa 555-
conjugated anti-rabbit antibodies (Molecular Probes) were used to detect pri-
mary antibodies. Nuclei were visualized by staining with Hoechst reagent at a
concentration of 0.5 g/ml. Microscopy was carried out using a Zeiss Axiovert
200 M inverted microscope equipped with fluorescence optics. Confocal images
were taken on a Zeiss LSM510 META laser scanning confocal microscope.
RESULTS
Identification of binding partners for GIPC1 by mass spec-
trometry. To identify potential interacting partners for GIPC1
within the nervous system, a GST fusion of full-length GIPC1
was incubated with adult rat brain lysate. Captured proteins
were resolved by SDS-PAGE and visualized by Coomassie
blue staining. This approach detected two bands, at 130 kDa
and 90 kDa, that bound specifically to GST-GIPC1 but not to
GST alone (Fig. 1). Analysis of the excised proteins by liquid
chromatography quadrupole time of flight assisted laser de-
sorption ionization mass spectrometry identified three proteins
as putative binding partners for GIPC1.
Ten peptides were detected within the 130-kDa band which
matched the sequence of the unconventional myosin myosin
VI. The isolation of myosin VI, a known interacting partner for
GIPC1 (5), confirmed the efficacy of the screen. The promi-
nent band, migrating at a relative molecular mass of 90 kDa,
yielded tryptic peptides homologous to sequences of two dif-
ferent proteins. Ten peptides were identified with sequence
corresponding to Huntingtin interacting protein 1 related
FIG. 1. Identification of APPL1 as a binding partner for GIPC1.
Cellular proteins precipitated with a GST fusion of full-length GIPC1
were isolated from adult rat brain extracts. Interacting proteins were
resolved by SDS-PAGE and detected by staining with Coomassie bril-
liant blue. Total cellular proteins representing the starting material
(SM) are shown in the first lane. Addition of GST alone to lysate and
incubation of GST-GIPC1 in the absence of lysate were included as
negative controls. The GST-GIPC1 band is marked with an arrow.
Bands specifically precipitated with GST-GIPC1 (marked with arrow-
heads) were excised from the gel and digested with trypsin. The re-
sulting peptides were sequenced by mass spectrometry.
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FIG. 2. The PDZ domain of GIPC1 binds directly to the C terminus of APPL1. (A) Schematic representations of the domain architecture of GIPC1
(left) and APPL1 (right). GST, Flag, and His epitope-tagged fusions of fragments and mutants of GIPC1 and APPL1 are shown. (B) GST fusions of
full-length GIPC1 or fragments of GIPC1 containing the PDZ domain specifically precipitate YFP-APPL1 from lysates of transfected COS7 cells. Cell
lysates were incubated with the GST fusion proteins as indicated, and the resulting complexes were analyzed by immunoblotting (IB) with anti-GFP
antibody. (C) The PDZ domain of GIPC1 is necessary and sufficient for direct association with the C-terminal region (C-term) of APPL1. Purified
fragments of APPL1 fused to a His epitope were incubated with purified, Sepharose-immobilized GST fusions of the GIPC1 N terminus (N-term), GIPC1
N terminus plus PDZ (N-term  PDZ), or GST alone. Anti-His antibody was used to detect His-APPL1 proteins by immunoblotting. (D) Removal of
the C-terminal alanine residue of APPL1 (
C-term Ala) abrogates its association with GIPC1. COS7 cells were transiently transfected to express either
wild-type Flag-APPL1 or Flag-APPL1 
C-term Ala. Cell lysates were incubated with GST fusion proteins as indicated and analyzed by immunoblotting
with anti-Flag antibody. Lysates of transfected cells show expression levels of the wild-type and truncated proteins. (E) Mutation of the carboxylate-
binding loop within the GIPC1 PDZ domain eliminates its interaction with APPL1. Flag-GIPC1 and the Flag-GIPC1 PDZ mutant were immunopre-
cipitated (IP) from transfected COS7 cells with anti-Flag antibody. Endogenous APPL1 associated with Flag-GIPC1 was detected with antibodies against
APPL1 (top). Levels of Flag-GIPC1 proteins were determined using the anti-Flag antibody (bottom).
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(HIP1R) peptide, and 16 peptides were detected correspond-
ing to APPL1. Consistent with the function of many of the
GIPC1-interacting proteins identified to date, HIP1R is a com-
ponent of clathrin-coated pits and vesicles, supporting a role
for GIPC1 in endocytosis (8). APPL1 plays a key role in en-
dosomal signaling that links events initiated by EGF at the
plasma membrane to chromatin remodeling in the nucleus
(26). Specialized endosomes containing TrkA have been
shown to relay NGF-mediated survival and differentiation sig-
nals from the axon to the cell body. Therefore, we chose to
investigate the interaction between APPL1 and GIPC1 in the
context of TrkA function.
The PDZ domain of GIPC1 interacts directly with the C
terminus of APPL1. In order to verify the interaction between
GIPC1 and APPL1, a GST fusion of full-length GIPC1 was
incubated with lysates of COS7 cells transfected to express
YFP-APPL1. Recovery of the fusion protein and immunoblot-
ting of bound proteins with anti-GFP antibody confirmed that
GIPC1 bound specifically to APPL1 and not the GST control
(Fig. 2B). The region of GIPC1 mediating the interaction was
defined using portions of GIPC1 protein fused to GST (Fig.
2A). Fragments encompassing the N-terminal region and the
PDZ domain of GIPC1 as well as the PDZ domain alone were
observed to bind to APPL1, whereas no interaction was de-
tected with the N-terminal or the C-terminal region of GIPC1
alone (Fig. 2B). These results indicate that the PDZ domain of
GIPC1 is necessary and sufficient for APPL1 binding.
To test whether the interaction was direct and to map the
binding site on APPL1, we incubated His-tagged fusions of
fragments of APPL1 spanning the length of the protein (Fig.
2A) with purified GST fusions of GIPC1. A GST fusion pro-
tein of the N-terminal region and PDZ domain of GIPC1
associated directly with the C-terminal third of APPL1 (Fig.
2C). No binding of this GIPC1 fragment was detected with the
N-terminal BAR domain or the central PH domain of APPL1.
These results are indicative of a direct interaction between the
PDZ domain of GIPC1 and the C-terminal sequence of
APPL1.
To evaluate if these regions of APPL1 and GIPC1 were
necessary for the proteins to interact, mutations in APPL1 and
GIPC1 which we predicted would disrupt their association
were generated. PDZ domains typically bind short sequences
of 4 to 5 residues at the extreme carboxy terminus of their
target protein. Mammalian APPL1 proteins possess a putative
PDZ domain binding site (ESEA-CO2H). Deletion of the C-
terminal alanine residue of APPL1 effectively abrogated its
binding to a GST fusion of the N-terminal region and PDZ
domain of GIPC1, confirming that the very C-terminal resi-
dues of APPL1 constitute a binding site for the GIPC1 PDZ
domain (Fig. 2D). In a complementary experiment, mutation
of each of the residues comprising the carboxylate-binding
loop of the GIPC1 PDZ domain to alanine eliminated its
association with APPL1 (Fig. 2E). Taken together, these ob-
servations clearly demonstrate that GIPC1 and APPL1 associ-
ate directly via a canonical interaction between the PDZ do-
main of GIPC1 and the short carboxy-terminal sequence of
APPL1.
APPL1 associates with GIPC1 in cells. GIPC1 has previ-
ously been reported to associate with TrkA in PC12 cells (24).
The identification of APPL1 as an interacting partner for
FIG. 3. GIPC1 and APPL1 associate in cells. (A) APPL1, TrkA, and pTrkA coprecipitate with GIPC1 in PC12 (6-24) cells. Endogenous GIPC1
was precipitated from lysates of cells treated with 50 ng/ml NGF for 10 min () or from untreated cells (). The presence of endogenous APPL1,
TrkA, and pTrkA in the precipitates was detected by immunoblotting (IB) with anti-APPL1, anti-TrkA, and antiphosphotyrosine antibodies,
respectively. Immunoprecipitation with preimmune serum (Pre-Imm IP) was included as a negative control. TrkA, pTrkA, APPL1, and GIPC1
proteins are marked with arrowheads. The upper band in the anti-GIPC1 immunoblot is the immunoglobulin heavy chain. (B) APPL1 copre-
cipitates with GIPC1 in rat primary sympathetic neurons. Endogenous GIPC1 was precipitated from sympathetic neuron lysates treated with 50
ng/ml NGF for 10 min. Immunoblots were probed with the indicated antibodies.
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GIPC1 provides a possible link between APPL1 and TrkA.
Therefore, we were interested in determining if APPL1 and
GIPC1 associate in cells where TrkA function has been char-
acterized extensively. PC12 cells and sympathetic neurons are
prototypical models for examining the requirement of TrkA
signaling for growth and survival. Since APPL1 expression has
not been reported for these cell types, we assessed expression
of APPL1 in PC12 (6-24) cells stably overexpressing TrkA and
in cultured sympathetic neurons from postnatal day 1 rat SCG.
Western blotting with an antibody generated against the PTB
domain of APPL1 detected robust levels of APPL1 in both cell
types (Fig. 3A and B). The subcellular localization of APPL1
and GIPC1 in sympathetic neurons was determined by immu-
nofluorescence staining. Endogenous APPL1 (Fig. 4A) and
endogenous GIPC1 (Fig. 4B) were present in a punctate pat-
tern in axons. The specificity of the pattern was confirmed by
staining in the absence of primary antibody as a negative con-
trol (Fig. 4C).
Having confirmed expression, we asked if endogenous
APPL1 and GIPC1 form complexes in these cells. To evaluate
whether APPL1 and GIPC1 exhibit a codistribution pattern,
sympathetic neurons were transiently transfected to express
Flag-GIPC1. Costaining with antibodies against the Flag
epitope and against APPL1 revealed a punctate colocalization
of Flag-GIPC1 and endogenous APPL1 in axons of transfected
cells (Fig. 4D to F). Next, we performed coprecipitation
experiments to determine if endogenous APPL1 and GIPC1
interact. Immunoprecipitation of GIPC1 coprecipitated APPL1
in both PC12 cells and sympathetic neurons (Fig. 3A and B).
Precipitation with preimmune serum did not yield detect-
able APPL1, indicating that the interaction is specific.
APPL1 was present at comparable levels in GIPC1 immu-
noprecipitates from untreated PC12 cells and from cells
treated with 50 ng/ml NGF for 10 min (Fig. 3A). This ob-
servation suggests that the interaction between APPL1 and
GIPC1 is not regulated by NGF treatment. In addition to
APPL1, TrkA was present in GIPC1 immunoprecipitates
from untreated as well as NGF-treated PC12 cells (Fig. 3A).
This result, previously reported by Lou et al. (24), is con-
sistent with a model whereby GIPC1 could act to bridge an
interaction between APPL1 and TrkA.
The PTB domain of APPL1 interacts directly with TrkA in a
phosphotyrosine-independent manner. In addition to the link
between APPL1 and TrkA through GIPC1, APPL1 could cou-
ple to TrkA through the PTB domain of APPL1 itself. Key
signaling molecules downstream of TrkA, including Shc and
FRS2, are recruited via their PTB domains to the tyrosine 490
docking site on TrkA, connecting TrkA to the Ras pathway.
The binding profile of the PTB domain of APPL1 has recently
been determined using peptides based on sequences of puta-
tive and known PTB domain-binding sites in the proteome
spotted on a peptide array. Utilizing this approach, the APPL1
PTB domain was shown to associate directly with peptides
corresponding to the Shc-binding site of TrkA and TrkC (M.
Smith and T. Pawson, personal communication).
To explore the possibility that the Shc-binding site of TrkA
might be involved in an association with APPL1, biotinylated
peptides containing a sequence corresponding to the Shc-bind-
ing site were bound to streptavidin Sepharose beads and incu-
bated with lysates of PC12 (6-24) cells. As a positive control,
the precipitated complex was immunoblotted with antibodies
against ShcA. Three isoforms of ShcA associated specifically
FIG. 4. APPL1 and GIPC1 share similar codistribution patterns in sympathetic neurons. Endogenous APPL1 (A) and GIPC1 (B) display
punctate patterns of distribution in axons of sympathetic neurons cultured in medium containing NGF. Neurons from newborn rat SCG were
immunostained with an antibody against APPL1 or GIPC1 as indicated. (C) As a negative control, primary antibody was omitted. (D) Anti-Flag
staining (red) of an axon from a sympathetic neuron transiently transfected to express Flag-GIPC1. (E) Distribution of endogenous APPL1 (green)
as determined by immunofluorescence staining with anti-APPL1 antibody. The same field is shown in panel D. Arrowheads mark examples of
Flag-GIPC1 and endogenous APPL1 codistribution (D and E). (F) Merged image of panels D and E. Bar, 10 m.
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with the TrkA peptide phosphorylated at tyrosine 490 but not
the unphosphorylated peptide, indicating the efficacy of the
peptides in binding their predicted targets (Fig. 5A). Reprob-
ing with antibodies against APPL1 determined that endoge-
nous APPL1 associated with the phosphorylated as well as the
unphosphorylated TrkA peptide but not to streptavidin beads
bound only to biotin (Fig. 5A). This result indicates that
APPL1 can associate with the Shc-binding site of TrkA in a
phosphotyrosine-independent manner.
Next, we sought to determine if the PTB domain of APPL1
could mediate its interaction with TrkA. A GST fusion of the
APPL1 PTB domain was incubated with lysates of sympathetic
neurons that were treated with 50 ng/ml NGF for 10 min or
were washed to remove NGF. The GST fusion encompassed
only the PTB domain (residues 472 to 655) of APPL1 and did
not include the C-terminal PDZ domain-binding site so that
the interaction of the PTB domain with TrkA could be as-
sessed independently of GIPC1 (Fig. 2A). We subjected the
resulting complexes to Western blotting with an antiphosphoty-
rosine antibody to detect endogenous pTrkA. pTrkA bound to
the GST fusion of the PTB domain of APPL1 but not to GST
alone (Fig. 5B). In this experiment, immunoblotting with the
antiphosphotyrosine antibody did not allow for the detection of
unphosphorylated TrkA. The blots from the GST pull-down ex-
periments were therefore also probed with antibodies against
TrkA. This approach revealed that GST-APPL1 PTB interacted
with TrkA in the lysate of sympathetic neurons treated with NGF
as well as in untreated cells (Fig. 5C). Consistent with the results
of the peptide mixing experiment, these data indicate that the
APPL1 PTB domain, like the PTB domains found in the X11,
Numb, and Fe65 proteins, does not require ligand phosphoryla-
tion for binding to its target sequences.
To determine if the interaction between the APPL1 PTB
domain and TrkA is direct, purified proteins were employed in
binding experiments. His-tagged fusions of the juxtamem-
brane, kinase, and C-terminal regions of TrkA were added to
GST fusions of the APPL1 BAR, PH, and PTB domains im-
mobilized on glutathione Sepharose beads. In mixing experi-
FIG. 5. The PTB domain of APPL1 binds directly to Trk receptors in a phosphotyrosine-independent manner. (A) APPL1 binds to TrkA peptides
corresponding to the Shc-binding site. Biotinylated phosphopeptide containing the TrkA sequence PHIIENPQpYFSD or the unphosphorylated version
of the peptide was bound to streptavidin beads and incubated with lysates of PC12 (6-24) cells. Streptavidin beads bound only to biotin were included
as a negative control. Endogenous APPL1 was detected by immunoblotting (IB) with anti-APPL1 antibodies, and blots were also probed with anti-ShcA
antibodies as a positive control. (B) pTrkA associates with the PTB domain of APPL1. NGF was withdrawn from primary cultures of sympathetic
neurons, and the cells were treated with 50 ng/ml NGF for 10 min () or left untreated (). Lysates were incubated with GST-APPL1 PTB or GST alone
as a negative control or were immunoprecipitated (IP) with a pan-Trk antibody as a positive control. Endogenous pTrkA representing the NGF-activated
form of TrkA was detected by immunoblotting with antiphosphotyrosine antibody. (C) The association between the APPL1 PTB domain and TrkA is
phosphotyrosine independent. Experiments were performed as described for panel B. Immunoblots were probed with anti-TrkA antibody to detect both
phosphorylated and unphosphorylated forms of TrkA. The mature, glycosylated TrkA protein is marked with an arrowhead. The additional lower band
in the TrkA immunoblot corresponds to an immature, underglycosylated form of TrkA. (D) The PTB domain of APPL1 interacts directly with the
juxtamembrane region of TrkA. A purified His-tagged fragment of TrkA containing the juxtamembrane region was incubated with GST fusions of the
APPL1 BAR, PH, and PTB domains or with GST alone. Purified His-TrkA juxtamembrane protein (50 ng) is included as a control. The immunoblot
was probed with antibody against the His tag.
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ments, only the APPL1 PTB domain exhibited binding to the
juxtamembrane region of TrkA that contains the Shc-binding
site (Fig. 5D). No binding of the APPL1 PTB domain to the
kinase or the C-terminal region of TrkA was detected (data not
shown). Taken together, these results clearly show that the
PTB domain of APPL1 can bind directly to TrkA in both its
tyrosine-phosphorylated and unphosphorylated forms.
Endogenous APPL1 associates with TrkA in sympathetic
neurons. Having identified two possible routes through which
APPL1 can couple with TrkA, we next evaluated whether
APPL1 and TrkA associate in sympathetic neurons. TrkA was
immunoprecipitated from a mass culture of neurons infected
with adenovirus encoding TrkA to elevate the level of the
receptor. Endogenous APPL1 specifically coprecipitated with
TrkA from infected neurons (Fig. 6A). The interaction ap-
peared to be independent of TrkA phosphorylation as it was
observed both in sympathetic neurons treated with 50 ng/ml
NGF for 10 min and in cells washed free of NGF. The speci-
FIG. 6. Endogenous APPL1 coprecipitates with TrkA. (A) Sympathetic neurons infected with Flag-TrkA adenovirus were subjected to NGF
withdrawal and then treated with 50 ng/ml NGF for 10 min (NGF) or left untreated (NGF). TrkA was immunoprecipitated (IP) from lysates
by use of an anti-pan-Trk antibody. Precipitation of lysates with protein A Sepharose (Prot A) alone and the incubation of pan-Trk antibody in
the absence of lysate were included as negative controls. Immunoblots (IB) were probed with the indicated antibodies. APPL1, pTrkA, and TrkA
bands are marked with arrowheads. The additional band in the TrkA immunoblot corresponds to an immature, underglycosylated form of TrkA.
(B) Association of endogenous APPL1 with TrkA does not require TrkA catalytic activity. Experiments were performed as described for panel A,
but cells were treated either with 200 nM of the inhibitor K252a in DMSO () or with DMSO alone (). (C) TrkA and APPL1 display partially
overlapping distributions in the axons of rat primary sympathetic neurons cultured in medium containing NGF. Confocal images were taken of
neurons stained with antibodies against APPL1 (green) or TrkA (red). The rightmost panel shows the merged image. Arrowheads mark examples
of the overlap between TrkA and APPL1 distribution. Bar, 5 m.
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ficity of the interaction was confirmed by the absence of
APPL1 in samples precipitated with protein A Sepharose
alone or with anti-TrkA antibodies in the absence of lysate.
To evaluate if TrkA catalytic activity was required for the
interaction with APPL1, similar experiments were performed
but in the presence or absence of the Trk inhibitor K252a.
Coprecipitation of endogenous APPL1 with TrkA was ob-
served whether the cells were treated with K252a in dimethyl
sulfoxide (DMSO) or with DMSO alone, demonstrating that
receptor autophosphorylation by the kinase domain of TrkA is
not required for the APPL1 interaction (Fig. 6B).
As another approach to examine the association of APPL1
with TrkA in sympathetic neurons, cultured neurons were sub-
jected to immunofluorescence staining to examine the distri-
bution of these proteins. Costaining to detect TrkA and
APPL1 determined a partially overlapping pattern of distribu-
tion along axonal tracts (Fig. 6C). Taken together, the coim-
munoprecipitation and immunofluorescence data indicate that
APPL1 and TrkA can associate in sympathetic neurons.
APPL1 and GIPC1 are present with phosphorylated TrkA in
endosomal fractions. APPL1 has been reported to localize to
endosomes that perform a signaling function downstream of EGF
(26). Having demonstrated an association between APPL1 and
TrkA, we were interested in determining if these proteins also
share a common endosomal distribution. To address this issue, we
performed a series of fractionation steps to separate different
populations of endosomes at a high resolution on the basis of
their physical properties. PC12 cells were treated with NGF for 10
min, a well-characterized time point at which most of the NGF is
present with the TrkA receptor in endocytic organelles (10, 11).
Endosomes were isolated from permeabilized cells and separated
first by their mass using velocity centrifugation. Five velocity gra-
dient fractions were collected, and each of these was subjected to
centrifugation through an equilibrium flotation gradient to re-
solve endocytic organelles by density.
Analysis of equilibrium gradient fractions by SDS-PAGE
and immunoblotting with antibodies against pTrkA (anti-
pY490), APPL1, and GIPC1 revealed that one population of
pTrkA-positive endosomes also contained APPL1 and GIPC1
(Fig. 7A and B). pTrkA, APPL1, and GIPC1 are present to-
gether in fractions 12 through 15, and all three proteins have a
peak at fraction 13, corresponding to a density of 1.12 g/ml.
This result, taken together with the coimmunoprecipitation
data, strongly suggests that these proteins associate in endo-
somes after treatment of PC12 cells with NGF. Interestingly,
APPL1 is also present in fractions 6 through 9, with a peak at
FIG. 7. pTrkA, APPL1, and GIPC1 are present together in endosomal subfractions. (A) Fractions of endosomes from NGF-treated PC12 cells
were isolated and then separated on the basis of size by velocity centrifugation. Five velocity gradient fractions were collected, and each pool was
further resolved on flotation equilibrium gradients. Data from an equilibrium gradient of velocity gradient fraction 2 are shown. Equilibrium
gradient fractions were collected such that endosomes of higher density are contained in lower-numbered fractions. Proteins were resolved by
SDS-PAGE, and the immunoblot (IB) was probed with the indicated antibodies. (B) Quantification and graphical representation of the data shown
in panel A. The density of each fraction was determined by refractive index measurements. Chemiluminescent signal strength from each of the
pTrk, APPL1, and GIPC1 bands was quantified and plotted against density. Data shown in panels A and B are representative of three separate
experiments.
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1.21 g/ml. In these fractions, pTrkA was not detectable. This
observation indicates that there is at least one other population
of endosomes bearing APPL1 that is not involved in TrkA
trafficking and signaling.
Reduction of APPL1 or GIPC1 levels decreases NGF-in-
duced MEK, ERK, and Akt activation. The interactions of
GIPC1 and APPL1 with TrkA suggest that these proteins play
a role in receptor function. To examine the functional conse-
FIG. 8. Reduction of APPL1 and GIPC1 protein levels by RNA interference decreases ERK and Akt activation but does not affect TrkA
tyrosine phosphorylation. (A) pERK and pAkt are reduced in APPL1 or GIPC1 siRNA-treated cells. PC12 (6-24) cells were transfected with
a negative-control siRNA or siRNAs targeting GIPC1 or APPL1. After NGF withdrawal, cells were treated with 50 ng/ml NGF for 10 min
(NGF) or left untreated (NGF). Equal amounts of cell extract (30 g total protein) were analyzed by immunoblotting (IB) with the
indicated antibodies. Levels of ERK1 and ERK2 were detected as a control for the specificity of the siRNA treatment. (B) MEK activation
is decreased whereas ShcA phosphorylation is unaffected in APPL1 and GIPC1 siRNA-treated cells. The same lysates from the experiments
described for panel A were probed with antibodies against pMEK, MEK, pShcA (pY317), ShcA, and Akt. (C) Neither TrkA levels nor levels
of TrkA total tyrosine phosphorylation are affected by reduction of APPL1 and GIPC1 protein levels. TrkA was immunoprecipitated (IP)
from 100 g of the lysates from the same experiment shown in panels A and B. Immunoblots were probed with antibodies against TrkA and
phosphotyrosine.
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quences of reducing APPL1 or GIPC1 protein levels on TrkA
signaling, PC12 (6-24) cells were transfected with synthetic
siRNAs targeting either APPL1 or GIPC1 or with a control
siRNA of random sequence. After 48 h, serum-starved cells
were treated with 50 ng/ml NGF for 10 min. Transfection of
PC12 (6-24) cells with siRNAs directed against GIPC1 or
APPL1 effectively and specifically reduced endogenous levels
of these proteins (Fig. 8A). Densitometric analysis of the blots
shown in Fig. 8A indicated an approximate reduction of
GIPC1 protein levels to 8% and 15% of the level observed for
cells treated with the control siRNA in the absence or presence
of NGF, respectively, upon GIPC1 siRNA treatment. APPL1
protein was detected at 39% and 48% of control levels for the
conditions without or with NGF, respectively, upon APPL1
siRNA treatment. The siRNA-mediated decrease of APPL1
did not affect GIPC1 levels, nor did reduction of GIPC1 affect
APPL1 levels. As expected, transfection of the control siRNA
had no effect on either APPL1 or GIPC1 levels. ERK1 and
ERK2 levels were unaffected in treated cells, confirming the
targeting specificity of the siRNAs.
NGF-induced signaling downstream of the TrkA receptor
was assayed by measuring levels of ERK, MEK, and Akt acti-
vation. In cells treated with either GIPC1 or APPL1 siRNAs,
NGF-induced ERK1 and ERK2 phosphorylation was signifi-
cantly diminished in comparison to cells treated with the con-
trol siRNA (Fig. 8A). Densitometric analysis revealed that
levels of NGF-mediated phosphorylation of ERK1 and ERK2
were reduced to 22% and 21% of control levels, respectively, in
APPL1 siRNA-treated cells. A decrease to 63% for pERK1
and 32% for pERK2 was observed for cells treated with GIPC1
siRNA. A similar pattern of reduction was observed when
NGF-stimulated MEK phosphorylation was evaluated (Fig.
8B). pMEK levels were decreased in APPL1 siRNA-treated
cells to 29% of control siRNA levels and GIPC1 siRNA-
treated cells to 41% of control siRNA levels. Examination of
phospho-Akt levels determined that NGF-induced Akt activa-
FIG. 9. Reduction of APPL1 or GIPC1 levels decreases NGF-induced neurite outgrowth. (A) GFP epifluorescence in fields of NGF-
differentiated PC12 (6-24) cells following siRNA treatment. Cells were cotransfected with the indicated siRNA and with pEGFP to allow for
visualization of neurites. Twenty-four hours following transfection, cells were differentiated by treatment with 50 ng/ml NGF for 48 h. Bar, 10 m.
(B) Effect of RNA interference-mediated reduction of APPL1 or GIPC1 levels on neurite outgrowth in PC12 (6-24) cells. Neurite lengths were
measured 48 h following NGF treatment, 72 h posttransfection. Mean neurite lengths per cell from three independent experiments (n  3) are
shown, along with standard errors. Cells treated with siRNAs targeting APPL1 or GIPC1 have significantly shorter average neurite lengths than
those transfected with the control siRNA (P  0.02, Bonferroni and Tukey tests on a paired design). (C) Levels of APPL1 and GIPC1 protein are
reduced in the cells shown in panel A. Following immunofluorescence analysis, cells were lysed and levels of APPL1 and GIPC1 were analyzed
by immunoblotting (IB) with the indicated antibodies. ERK levels provided a control for equal loading.
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tion was also reduced in PC12 (6-24) cells transfected with
APPL1 siRNA to 39% of control siRNA levels or with GIPC1
siRNA to 61% of control siRNA levels (Fig. 8A). In addition,
we examined the tyrosine phosphorylation of ShcA and FRS2,
two proximal targets of TrkA known to regulate MEK and
MAPK activity. We did not detect a reduction in the tyrosine
phosphorylation of ShcA (Fig. 8B) or FRS2 (data not shown)
in cells treated with APPL1 or GIPC1 siRNA. These results
indicate that APPL1 and GIPC1 are involved in activation of
the MAPK pathway as well as the PI 3-kinase/Akt pathway
downstream of TrkA and ShcA but upstream of MEK.
One possible explanation for the reduction in both pERK
and pAkt levels is that NGF-induced TrkA activation may be
compromised as a result of reduced APPL1 or GIPC1 levels.
To test this possibility, we immunoprecipitated TrkA from
lysates of the same experiment described above and examined
its level of phosphorylation by use of an antiphosphotyrosine
antibody. In contrast to the effects on ERK and Akt activation,
TrkA total phosphorylation was not affected by the down-
regulation of endogenous APPL1 or GIPC1 (Fig. 8C). These
data demonstrate that GIPC1 and APPL1 function in NGF-
induced ERK and Akt phosphorylation downstream of TrkA
activation.
Neurite outgrowth is diminished in cells with decreased
APPL1 or GIPC1 levels. Having determined a requirement for
APPL1 and GIPC1 in NGF-induced ERK and Akt activation,
we next investigated whether these proteins were necessary for
biological outcomes mediated by NGF signaling. We explored
this possibility by using PC12 cells as a model to examine the
role of GIPC1 and APPL1 in NGF-induced neurite extension.
PC12 (6-24) cells plated on poly-L-lysine to assist in their dif-
ferentiation were cotransfected with pEGFP and siRNA oligo-
nucleotides. After 24 h, cells were differentiated for 2 days in
media containing 50 ng/ml NGF. Expression of GFP was used
to visualize neurites in transfected cells. The ratio of pEGFP
DNA to siRNA oligonucleotide was optimized so that the
majority of GFP-positive cells were cotransfected with the
siRNA (data not shown).
Examination of neurite length revealed that, in comparison
to cells treated with the control siRNA, cells extended short
processes when APPL1 or GIPC1 levels were reduced by
siRNA treatment (Fig. 9A). We quantified this effect by mea-
suring the neurite lengths of GFP-positive cells. Compared
with an average length of 50.7  7.4 m per cell for the control
siRNA-treated cells, cells treated with APPL1 siRNA and
GIPC1 siRNA had an average neurite length of 28.2  6.8 m
per cell and 30.8  9.2 m per cell, respectively (Fig. 9B).
Thus, reduced levels of APPL1 or GIPC1 significantly attenu-
ated NGF-induced neurite outgrowth relative to that for con-
trol-treated cells (P  0.02). This effect on growth is consistent
with the observed decrease in NGF-mediated activation of the
ERK pathway. Following the capture of images by immuno-
fluorescence microscopy, the cells were lysed and proteins lev-
els examined by immunoblotting with antibodies against
GIPC1, APPL1, and ERK. APPL1 and GIPC1 protein levels
were reduced upon treatment with their respective siRNAs,
while ERK levels were unaffected, confirming the effective
knockdown of endogenous APPL1 or GIPC1 protein levels in
these cells (Fig. 9C).
Since we observed a reduction in the activation of the Akt
pathway as a result of knockdown of APPL1 or GIPC1 protein
levels, we assayed for effects on cell survival. We performed
Hoechst staining on the siRNA-treated, NGF-differentiated
PC12 (6-24) cells. Analysis revealed that 3.2%  0.9% of
control siRNA-treated, 7.6%  1.7% of GIPC1 siRNA-
treated, and 6.2%  0.8% of APPL1 siRNA-treated cells dis-
played condensed or fragmented nuclei, indicative of apopto-
sis. To further verify that the siRNA-treated cells were not
simply undergoing widespread cell death, survival was quanti-
fied by an MTT assay that measures mitochondrial function.
When standardized to a value of 100% for the control siRNA-
treated cells, MTT readings for GIPC1 siRNA-treated cells
were an average of 92.5%  3% (n  3) and readings for
APPL1 siRNA-treated cells were 91.4%  5.3% (n  3). The
limited extent of apoptosis as assayed by both Hoechst staining
and MTT assay suggests that the effects of reducing APPL1 or
GIPC1 protein levels on neurite length are not a consequence
of an impact upon cell survival but rather result from a per-
turbation of neurite outgrowth mediated by the ERK pathway
downstream of the TrkA receptor.
DISCUSSION
In this report, we have identified APPL1 as a novel TrkA-
associated protein in neurons. APPL1, which is known to play
roles in endosomal signaling and Akt regulation, was also
found to be associated with GIPC1, another TrkA-interacting
protein previously shown to cluster with TrkA in intracellular
vesicles. The association of APPL1 and TrkA could occur by at
least two mechanisms, one requiring GIPC1 and the second
through the direct binding of the APPL1 PTB domain to TrkA.
The binding of APPL1 to GIPC1 was mediated by the C-
terminal region of APPL1 and the PDZ domain of GIPC1.
APPL1, GIPC1, and activated TrkA cofractionated in the
same highly purified endosomal membrane preparation from
PC12 cells. Both APPL1 and GIPC1 were required for TrkA
signal transduction, as reduction of the levels of either of these
proteins suppressed NGF-stimulated ERK1/2 and Akt activa-
tion and neurite outgrowth in PC12 cells.
What is the function of APPL1 in NGF-mediated signal
transduction? We found that the suppression of APPL1 levels
inhibited NGF-mediated Akt and Erk activation, which are
required for NGF-mediated survival and neuritogenesis, re-
spectively (19). APPL1 has been reported to be a direct bind-
ing partner for Akt2 and postulated to potentiate Akt activa-
tion by tethering this kinase to PI 3-kinase (27). Consistent
with this hypothesis, APPL1 enhanced Akt-mediated suppres-
sion of androgen receptor transactivation in a PI 3-kinase-
dependent manner and was required for Akt phosphorylation
on serine residue 473 in response to insulin-like growth factor
in PC-3 cells (38). A similar role for APPL1 is suggested by our
observation that reducing APPL1 levels decreased NGF-me-
diated Akt phosphorylation. The reduction of Akt activity by
suppression of APPL1 levels, however, did not suppress NGF-
induced PC12 cell survival, likely because the residual levels of
Akt were sufficient to mediate survival. In support of this
conclusion, sympathetic neurons are known to require 10-fold
less NGF for survival than for axonal growth (3).
Our experiments also revealed a requirement for APPL1 in
NGF-induced activation of MEK and ERK1/2 but not TrkA
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activation or ShcA phosphorylation. In PC12 cells and sympa-
thetic neurons, activation of the MAPK pathway is required for
NGF-mediated neuritogenesis (19). Consistent with this role
of the MAPK pathway downstream of NGF, we demonstrated
that the suppression of APPL1 levels also attenuated NGF-
induced neuritogenesis. Interestingly, APPL1 was previously
shown to weakly associate with Grb2 (27), an adaptor protein
that regulates TrkA-induced MAPK activity, providing a pos-
sible means by which APPL1 regulates the activity of this
pathway.
The observation that APPL1 associates with TrkA and co-
fractionates with TrkA in a subpopulation of endosomes is
consistent with a model whereby APPL1 may function in en-
dosomal signaling downstream of NGF. APPL proteins have
previously been implicated in an EGF-induced endosomal sig-
naling pathway that links trafficking events at the plasma mem-
brane to chromatin remodeling in the nucleus (26). In EGF-
treated HeLa cells, APPL was required for EGF-induced cell
proliferation through uptake of EGF into APPL- and Rab5-
containing endosomes at membranes and transport and re-
lease of APPL to the nuclear compartment. While we have
thus far not observed an NGF-mediated translocation of
APPL1, the association between these proteins may serve to
couple NGF-TrkA endosomal signaling complexes to other
trafficking events governed by the Rab proteins. This hypoth-
esis is consistent with the emerging theme that Rab GTPases
are significant players in TrkA trafficking and signaling. In-
deed, Rab7 was recently identified to associate with TrkA to
regulate the signaling endosome residence time (29) and Rab5
has been found with GIPC1, APPL1, and pTrkA in endosomal
fractions of NGF-treated PC12 cells (M. Grimes, personal
communication).
We found that APPL1 associated with GIPC1, a TrkA-bind-
ing protein that has previously been shown to be required for
activation of NGF-induced MAPK signaling (24). We show
that GIPC1 is also required for efficient NGF-induced neurite
outgrowth, as well as activation of MEK, MAPK, and Akt. The
precise mechanism through which GIPC1 mediates these func-
tions remains to be elucidated. However, the observed effects
of reducing GIPC1 levels are similar to those of decreasing
APPL1 levels. Furthermore, we have identified a direct PDZ
domain-mediated association between GIPC1 and APPL1 and
have detected APPL1, GIPC1, and phosphorylated TrkA in
the same endosomal fractions. Based on these observations, we
propose that GIPC1 may function as a bridging protein to
connect APPL1 with TrkA. Despite containing only a single
protein-protein interaction domain, GIPC1 has been hypoth-
esized to function as a scaffolding molecule to organize multi-
protein complexes. Interestingly, mutation of the carboxylate
binding loop of the GIPC1 PDZ domain does not abolish the
interaction between TrkA and GIPC1, raising the possibility
that the binding pocket of the GIPC1 PDZ domain remains
open to recruit other proteins (24). Therefore, it is conceivable
that GIPC1 can simultaneously engage both TrkA and APPL1
since the binding of the internal sequence in the juxtamem-
brane region of TrkA occurs at a site within the GIPC1 PDZ
domain that is distinct from the carboxylate binding pocket
that interacts with the C-terminal sequence of APPL1. An-
other mechanism by which GIPC1 can organize higher-order
complexes containing both APPL1 and TrkA is through the
ability of GIPC1 to multimerize, a process involving its N-
terminal domain (5). This versatility in protein interactions
allows GIPC1 to bridge distinct pathways by simultaneously
binding different proteins. For example, GIPC1 can recruit
GAIP, a regulator of heterotrimeric G proteins, to TrkA (24)
and to the D2R dopamine receptor (17). We suggest that
GIPC1 may play an important role in TrkA function by bridg-
ing the association between APPL1 and TrkA.
The APPL1 PTB domain bound TrkA directly without the
involvement of GIPC1. The availability of both GIPC1-depen-
dent and GIPC1-independent routes for APPL1 association
with TrkA suggests that the composition of the internalized
TrkA signaling complex may be dynamic. One possibility is
that the GIPC-dependent association may be important in
early events after TrkA activation while the GIPC1-indepen-
dent interaction comes into play during later events. Several
lines of evidence suggest GIPC1 is involved in endocytosis and
early trafficking events after receptor internalization. In non-
neuronal cells, GIPC1 localizes to membrane-associated vesi-
cles and tubular structures and to clathrin-coated pits (23). We
have shown the presence of GIPC1, APPL1, and activated
TrkA in endosomal fractions 10 min after NGF treatment.
This observation is in agreement with fractionation studies
with PC12 cells and cortical neurons showing similar profiles of
enrichment within fractions of intracellular membranes for
GIPC1 and Trk (39). During the course of TrkA endocytosis
and trafficking, however, GIPC1 or APPL1 may not remain
associated with TrkA. The dissociation of GIPC1 from vesicles
after fusion with early endosomes in epithelial cells (1) and
nonexhaustive colabeling of GIPC1 with D2R and D3R dopa-
mine receptors (16) suggest that GIPC1 is released during later
sorting events. At these later time points, GIPC1-independent
binding via the APPL1 PTB domain may be the mechanism
through which TrkA and APPL1 continue to associate in neu-
ronal cells.
Based upon our observations, we propose a model whereby
APPL1 and GIPC1 are constitutively bound to TrkA. Upon
activation of TrkA by NGF, APPL1 potentiates Akt activation
at the plasma membrane. Both GIPC1 and APPL1 are co-
internalized with activated TrkA, residing in a population of
endosomes that target TrkA to signaling proteins, such as
MAPK, or to the nuclear membrane. Future experiments as-
sessing the effect of disrupting APPL1, GIPC, and TrkA inter-
actions in primary neurons in compartmentalized cultures will
allow us to further elucidate the role of these proteins in the
transmission of NGF retrograde signals.
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